We identify the ERN1-JNK-JUN pathway as a novel regulator of MEK inhibitor response in KRAS mutant colon cancer, and point to synthetic lethality of MEK inhibition with therapeutics targeting JUN activating kinases, TAK1 and JNK. Here, ERN1 is linked to malignant colon neoplasm.